Clinical trials: Overweight and Obesity
Metabolism and Nutrition Disorder, Obesity
Awareness, Care and Treatment in Obesity Management
This study aims to assess barriers that prevent obesity patients from receiving adequate care for their condition. The non-interventional study will be administered in the form of a 30-minute, cross-sectional, online survey to…
- Trial name
- NCT03235102
- Testing
- No treatment given
- Where
- Canada
- Volunteers
- 2,545 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake.
- Trial name
- NCT06267092
- Testing
- No treatment given, Cagrilintide and Semaglutide
- Where
- Germany
- Volunteers
- 164 people
- Sponsor
- Novo Nordisk A/S
Obesity
Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
This was a multi-center, randomized, placebo-controlled, participant-and-investigator-blinded, sponsor open-label study in obese participants with or without Type 2 Diabetes Mellitus.
- Trial name
- NCT05199090
- Testing
- MBL949
- Where
- 4 sites in United States
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)
To study different doses of MK0493 for safety, efficacy and tolerability in obese patients.
- Trial name
- NCT00482196
- Testing
- MK0493
- Volunteers
- 173 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
Study of Coffee Mannooligosaccharides for Weight Management
The goal of this study is to establish the role of coffee mannooligosaccharides (MOS), provided in a beverage format, on body weight regulation.
- Trial name
- MOS (NCT00932750)
- Testing
- Coffee mannooligosaccharide, Coffee mannooligosaccharides
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Mondelēz International, Inc.
Genetic Disorder, Prader-Willi Syndrome
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
This trial is conducted in United States of America (USA). The aim of this trial is to examine the bioequivalence of Norditropin® versus Genotropin® in healthy adult volunteers.
- Conditions
- Genetic Disorder, Prader-Willi Syndrome, Growth Disorder, Idiopathic Short Stature
- Trial name
- NCT01401244
- Testing
- somatropin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Obesity
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity.
- Trial name
- NCT06970405
- Testing
- Garetosmab
- Sponsor
- Regeneron Pharmaceuticals
Obesity
Study of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner
The purpose of this study is to determine whether the GI Endobarrier Liner can be reimplanted.
- Trial name
- NCT01372501
- Testing
- Endobarrier Liner
- Where
- Chile
- Volunteers
- 19 people
- Sponsor
- Morphic Medical Inc.
Obesity, Overweight
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in treating obesity and leads to greater weight loss when given with a group lifestyle modification program…
- Trial name
- NCT00456521
- Testing
- Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Intensive group lifestyle modification counseling
- Where
- 9 sites in United States
- Volunteers
- 793 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity, Weight Change Trajectory
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both…
- Conditions
- Obesity, Weight Change Trajectory, Weight Change, Body
- Trial name
- REMAIN-1 (NCT06484114)
- Testing
- Revita Duodenal Mucosal Resurfacing (DMR)
- Where
- 32 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Fractyl Health Inc.
Overweight or Obesity
A Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose of SYH2082 Injection in healthy participants.
- Trial name
- NCT07736404
- Testing
- SYH2082 Injection
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Overweight, Obesity
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study.
- Trial name
- NCT03856047
- Testing
- NNC0174-0833, Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 8 more
- Volunteers
- 706 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity, Healthy
the Safety, Tolerability and Pharmacokinetics of Mulberry Twig Alkaloids in Human
This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, and pharmacokinetics of the Mulberry Twig Alkaloids tablets (WH006) in healthy ，overweight and obesity subjects.
- Trial name
- NCT06490263
- Testing
- Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects, Mulberry Twig Alkaloids Tablets with single dose in healthy subjects, Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Beijing Wehand-Bio Pharmaceutical Co., Ltd
Obesity
Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients
The purpose of this study is: To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in treatment of obese patients.
- Trial name
- NCT01535014
- Testing
- Dietressa
- Where
- 17 sites in Russia
- Volunteers
- 493 people
- Sponsor
- Materia Medica Holding
Overweight or Obesity
A Study of ZT002 Injection With Subjects With Overweight or Obesity
This study will evaluate the percentage change from baseline in weight after 24 weeks of treatment with ZT002 Injection in subjects with overweight/obesity.
- Trial name
- NCT07020884
- Testing
- ZT002 Injection
- Where
- 16 sites in China
- Volunteers
- 303 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
- Conditions
- Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes
- Trial name
- TREASURE-CKD (NCT05536804)
- Testing
- Tirzepatide
- Where
- 27 sites in United States, Austria and 4 more
- Volunteers
- 134 people
- Sponsor
- Eli Lilly and Company
Change in Total Body Fat Mass Percentage Loss Versus Body Weight
Evaluation of Sinetrol® Xpur in Fat Mass Reduction on Overweight and Obese Subjects
This study aims to evaluate effects of a 16-week supplementation with a polyphenol rich extract, Sinetrol® Xpur, on fat mass accumulation and body weight management improvement.Subjects were overweight or obese and received…
- Trial name
- NCT04149158
- Testing
- Sinetrol® Xpur
- Where
- Spain
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Fytexia
Obesity, Type 2 Diabetes
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adult subjects with type 2 diabetes mellitus.
- Trial name
- NCT02324491
- Testing
- ZGN-440 for Injectable Suspension
- Where
- 16 sites in Australia
- Volunteers
- 152 people
- Sponsor
- Zafgen, Inc.
Healthy
A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers. Primary Objectives: 1.
- Trial name
- NCT00776841
- Testing
- Aramchol
- Where
- Israel
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Galmed Medical Reserch
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.